Analytical Data
-
Gene name
NKG2A
- Application
-
Alternative Names
CD159a; NKG2A; NKG2-A; CD94; NKG2A&CD94
-
Species
Cynomolgus
-
Source
HEK293
-
Tag
C-8*His;C-Flag
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q68VD2 (P94-L233)&Q68VD4
-
Expression Region
Q68VD2 (P94-L233)&Q68VD4 (K32-I179)
-
Molecular Weight
25-35 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NKG2A is an inhibitory receptor primarily expressed on natural killer (NK) cells and some T cells, playing a crucial role in regulating immune responses. It interacts with its ligand, HLA-E, which presents peptides derived from major histocompatibility complex (MHC) class I molecules. This interaction is vital for maintaining immune tolerance and preventing autoimmunity. Research on NKG2A has gained traction due to its implications in cancer immunotherapy; tumors often exploit this pathway to evade immune detection by upregulating HLA-E expression, leading to decreased NK cell activity. Consequently, targeting NKG2A via monoclonal antibodies has emerged as a promising strategy in enhancing anti-tumor responses, making it a focal point in studies aimed at improving cancer treatment efficacy. Recent advancements in recombinant protein technology have facilitated the production of NKG2A-Fc fusion proteins, which can be used to block NKG2A’s inhibitory signals and restore NK cell function against malignancies. These innovations not only enhance our understanding of the immune evasion mechanisms employed by tumors but also pave the way for novel therapeutic interventions that can potentially improve patient outcomes in immuno-oncology.
